Metropolitan Life Insurance Company (MetLife)’s Vanda Pharmaceuticals VNDA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,471	Closed	-$6.05K	–	2051
2024 Q1	$6.05K	Sell	1,471 -1,594	-52%	-$6.38K	﹤0.01%	2233
2023 Q4	$12.9K	Hold	3,065	–	–	﹤0.01%	2089
2023 Q3	$13.2K	Hold	3,065	–	–	﹤0.01%	2088
2023 Q2	$20.2K	Buy	3,065 +1,325	+76%	+$8.49K	﹤0.01%	1924
2023 Q1	$11.8K	Sell	1,740 -1,848	-52%	-$13K	﹤0.01%	2094
2022 Q4	$26.5K	Hold	3,588	–	–	﹤0.01%	1851
2022 Q3	$35.4K	Hold	3,588	–	–	﹤0.01%	1693
2022 Q2	$39.1K	Hold	3,588	–	–	﹤0.01%	1656
2022 Q1	$40.6K	Sell	3,588 -11,217	-76%	-$147K	﹤0.01%	1714
2021 Q4	$232K	Buy	14,805 +1,386	+10%	+$24.2K	﹤0.01%	1923
2021 Q3	$230K	Sell	13,419 -2,880	-18%	-$50.4K	﹤0.01%	1962
2021 Q2	$351K	Buy	16,299 +1,648	+11%	+$29.5K	﹤0.01%	1750
2021 Q1	$220K	Buy	14,651 +2,122	+17%	+$34.4K	﹤0.01%	1949
2020 Q4	$165K	Sell	12,529 -4,465	-26%	-$53.7K	﹤0.01%	2065
2020 Q3	$164K	Hold	16,994	–	–	﹤0.01%	1906
2020 Q2	$194K	Hold	16,994	–	–	﹤0.01%	1813
2020 Q1	$176K	Buy	16,994 +664	+4%	+$8.23K	﹤0.01%	1665
2019 Q4	$268K	Sell	16,330 -857	-5%	-$13K	﹤0.01%	1712
2019 Q3	$228K	Hold	17,187	–	–	﹤0.01%	1789
2019 Q2	$242K	Hold	17,187	–	–	﹤0.01%	1767
2019 Q1	$316K	Hold	17,187	–	–	0.01%	1595
2018 Q4	$449K	Hold	17,187	–	–	0.01%	1258
2018 Q3	$394K	Hold	17,187	–	–	0.01%	1532
2018 Q2	$327K	Buy	17,187 +2,671	+18%	+$44.7K	0.01%	1597
2018 Q1	$245K	Hold	14,516	–	–	﹤0.01%	1766
2017 Q4	$221K	Buy	+14,516	New	+$215K	﹤0.01%	1858
2017 Q3	–	Sell	-29,606	Closed	-$483K	–	2530
2017 Q2	$483K	Hold	29,606	–	–	﹤0.01%	1719
2017 Q1	$414K	Hold	29,606	–	–	﹤0.01%	1784
2016 Q4	$472K	Hold	29,606	–	–	﹤0.01%	1778
2016 Q3	$493K	Hold	29,606	–	–	﹤0.01%	1719
2016 Q2	$331K	Hold	29,606	–	–	﹤0.01%	1956
2016 Q1	$248K	Hold	29,606	–	–	﹤0.01%	2047
2015 Q4	$276K	Hold	29,606	–	–	﹤0.01%	2029
2015 Q3	$334K	Hold	29,606	–	–	﹤0.01%	1906
2015 Q2	$376K	Sell	29,606 -2,233	-7%	-$24.1K	﹤0.01%	1948
2015 Q1	$296K	Hold	31,839	–	–	﹤0.01%	1852
2014 Q4	$456K	Buy	31,839 +6,559	+26%	+$77.6K	﹤0.01%	1822
2014 Q3	$262K	Hold	25,280	–	–	﹤0.01%	2184
2014 Q2	$409K	Hold	25,280	–	–	﹤0.01%	1985
2014 Q1	$411K	Hold	25,280	–	–	﹤0.01%	1950
2013 Q4	$314K	Hold	25,280	–	–	﹤0.01%	2152
2013 Q3	$277K	Hold	25,280	–	–	﹤0.01%	2170
2013 Q2	$204K	Buy	+25,280	New	+$170K	﹤0.01%	2346

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s VNDA Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Vanda Pharmaceuticals (VNDA) in Q2 2024, closing a stake of 1,471 shares — an estimated $6.05K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in VNDA in Q2 2013 and held it in 43 quarters. The position peaked at $493K in Q3 2016. 148 funds tracked by Wall St. Rank hold VNDA as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Vanda Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,471 Vanda Pharmaceuticals shares in Q2 2024, an estimated $6.05K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 43 quarters.
Metropolitan Life Insurance Company (MetLife)'s Vanda Pharmaceuticals position peaked at $493K in Q3 2016.
148 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.